Compare MYGN & OSPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | OSPN |
|---|---|---|
| Founded | 1991 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.2M | 449.1M |
| IPO Year | 1995 | 1998 |
| Metric | MYGN | OSPN |
|---|---|---|
| Price | $5.11 | $11.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $10.67 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 945.4K | 654.4K |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 4.27% |
| EPS Growth | N/A | ★ 99.92 |
| EPS | N/A | ★ 1.49 |
| Revenue | ★ $825,300,000.00 | $241,436,000.00 |
| Revenue This Year | $0.05 | $0.69 |
| Revenue Next Year | $5.54 | $1.96 |
| P/E Ratio | ★ N/A | $7.55 |
| Revenue Growth | ★ 0.21 | N/A |
| 52 Week Low | $3.76 | $10.17 |
| 52 Week High | $15.47 | $20.37 |
| Indicator | MYGN | OSPN |
|---|---|---|
| Relative Strength Index (RSI) | 27.66 | 32.35 |
| Support Level | $5.03 | $10.17 |
| Resistance Level | $5.70 | $12.21 |
| Average True Range (ATR) | 0.28 | 0.48 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 8.93 | 29.45 |
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.